A Q&A with Jan De Backer
Founded iin 2005, FLUIDDA provides respiratory solutions for better patient care. As a major player in the field of Quantitative Pulmonary CT, FLUIDDA leads the pack with its proprietary Functional Respiratory Imaging (FRI) technology. This technique combines HRCT scans and Computational Fluid Dynamics technology, which offers vast improvements by making clinical trials shorter, faster, and more cost effective.
FRI also helps patients and healthcare providers in offering a unique entry point in personalized medicine, by optimizing diagnosis, monitoring disease progression, and the effects of therapy. FLUIDDA’s goal is to improve the lives of people suffering from respiratory diseases by optimizing treatment pathways, reducing healthcare costs, and limiting the go-to-market time of respiratory drugs, pulmonology medical devices, and therapies.
This passion for innovation drove FLUIDDA to become a founding member of OSIC. From the start, FLUIDDA has shared its expertise and learnings with us and has been a key influence in shaping our mission and driving our strategic direction.
We spoke with FLUIDDA CEO Jan De Backer, who also serves on our board of directors, about what first brought him to OSIC, the unique perspective that FLUIDDA brings to our organization, and where he sees OSIC five years down the line. Following is an excerpt from our conversation.
Collaboration and access to data help drive medical innovation. “The future of medical research depends heavily on our ability to collate significant amounts of data, and make that data available for detailed and open scientific investigation,” said Dr. David Barber, University College London and OSIC computation science lead. “It’s a proud moment that OSIC is at the forefront of this movement.”